8-K: Septerna Presents at TD Cowen Conference, Highlighting GPCR Drug Discovery Platform and Pipeline

Septerna, Inc. presents at the TD Cowen 45th Annual Health Care Conference, showcasing its Native Complex Platform for GPCR drug discovery and its portfolio of oral small molecule programs.

Summary

• Septerna, Inc. is focused on pioneering a new era of GPCR drug discovery with oral small molecules.
• The company's Native Complex Platform is designed to unlock the full potential of GPCR therapies.
• Septerna is utilizing iterative structure-based drug design to rapidly optimize and validate programs in animal models.
• The company has a portfolio strategy to drive value creation, focusing on validated targets with early clinical readouts and multi-billion dollar market opportunities.
• Septerna is well-capitalized with a planned operating runway into at least the second half of 2027.
• The company's lead programs include a PTH1R agonist for hypoparathyroidism, SEP-631 (MRGPRX2 NAM) for mast cell diseases, and a TSHR NAM for Graves disease and thyroid eye disease.
• Septerna is also developing incretin receptor agonists for metabolic diseases like obesity and type 2 diabetes.
• The company discontinued development of SEP-786 due to unexpected elevated bilirubin levels in a Phase 1 trial, but is advancing next-generation PTH1R agonists.
• Septerna expects to initiate a Phase 1 clinical trial for SEP-631 in 2025.
• The company is building a world-class GPCR-focused biotechnology company with proven leaders in GPCR drug development.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the discontinuation of SEP-786 is a setback, the company is advancing next-generation candidates and has a strong platform and pipeline. The well-capitalized status and experienced management team also contribute to the positive outlook.

Positives

• Septerna's Native Complex Platform is designed to unlock the full potential of GPCR therapies.
• The company is well-capitalized with a planned operating runway into at least the second half of 2027.
• The company has a multi-product pipeline, each with multi-billion dollar market opportunity.
• The company's Native Complex Platform drives rapid compound identification and portfolio expansion.
• The company has identified multiple chemically distinct PTH1R agonists with favorable pharmacokinetics profiles.
• The company's next-generation PTH1R agonists are predicted to have superior human PK properties compared to SEP-786.
• SEP-631 has demonstrated good PK properties and has been generally well tolerated in preclinical safety models to date.
• The company's TSHR NAMs have reversed symptoms in a novel Graves disease model.
• The company has identified multiple incretin receptor agonist chemical series with activity spanning combinations of activities across GLP-1R, GIPR, and GCGR.

Negatives

• The company discontinued development of SEP-786 due to unexpected elevated bilirubin levels in a Phase 1 trial.
• The company's decision to discontinue SEP-786 development may delay the timeline for its hypoparathyroidism program.

Risks

• The company's forward-looking statements are subject to known and unknown risks and other factors, which are, in some cases, beyond the company's control.
• The company's estimates regarding expenses and capital requirements may be inaccurate.
• The company's product candidates may not be successful in clinical trials.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may face competition from other companies developing GPCR-targeted therapies.
• The company's reliance on its Native Complex Platform may limit its ability to develop drugs targeting other types of receptors.

Future Outlook

Septerna plans to continue developing and advancing its oral small molecule GPCR-targeted programs, including selecting a next-generation oral PTH1R agonist product candidate and initiating the SEP-631 clinical trial. The company expects to demonstrate preclinical proof-of-concept in vivo and ex vivo for multiple programs.

Industry Context

The presentation highlights the significant untapped potential in GPCR drug discovery, as historically only a small fraction of GPCRs have been successfully targeted. Septerna's Native Complex Platform aims to address this challenge by enabling the discovery of drugs targeting difficult-to-drug GPCRs. The company is also targeting metabolic diseases, where incretin peptide therapeutics have already achieved significant market success, with the goal of developing next-generation oral small molecule agonists.

Comparison to Industry Standards

• The document mentions Vertex acquiring an undisclosed discovery-stage program in 2023 for $47.5M upfront, providing a benchmark for potential value of Septerna's programs.
• The document references marketed GLP-1 and GLP-1/GIP products generating ~$36B in global sales in 2023, highlighting the significant market opportunity in metabolic diseases.
• The document mentions TEPEZZA (anti-IGF-1R) as a treatment for TED, but notes its limitations, including the need for multiple IV infusions and serious side effects, highlighting the potential for Septerna's oral TSHR NAM to offer a more convenient and safer alternative.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through successful drug development.
• Patients: Potential for new and improved treatments for hypoparathyroidism, mast cell diseases, Graves disease, thyroid eye disease, obesity, and type 2 diabetes.
• Employees: Opportunity to work on innovative drug discovery programs.
• Partners: Potential for collaborations and licensing agreements.

Next Steps

• Select a next-generation candidate to accelerate toward clinical development later this year.
• Initiate Phase 1 clinical trial for SEP-631 in 2025.
• Continue optimizing singleand multi-incretin agonist leads.

Key Dates

Keywords

GPCR, Native Complex Platform, Drug Discovery, Hypoparathyroidism, Mast Cell Diseases, Graves Disease, Thyroid Eye Disease, Obesity, Type 2 Diabetes, PTH1R Agonist, MRGPRX2 NAM, TSHR NAM, Incretin Receptor Agonists